Discover

Back to filter

Related topics

High quality Bioluminescence and X-Ray analysis in lung squamous cell carcinoma

Spectral Instruments Imaging

Jul 21, 2021

Spectral Instruments Imaging provides unrivaled sensitivity for bioluminescence,...

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jul 15, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full...

Webinar recording: Autofluorescence management - the power of Spectral Flow Cytometry

Cytek Biosciences

Jul 15, 2021

One of the key advantages of spectral flow cytometry is its ability to extract sample...

Webinar recording: Super-Resolution imaging of Chromatin organization in health and disease

ONI

Jul 9, 2021

Understanding how cells organize the array of components within their membranous confines can not only provide insight...

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles

Spectral Instruments Imaging

Jul 3, 2021

Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma....

Quantitative two-photon microscopy imaging analysis of human skin

IVIM Technology

Jul 1, 2021

Transdermal skin delivery is a method to transport various topical formulations to a deeper skin layer non-invasively....

Show all topics (10)

xCELLigence in personalized cancer medicine

Dec 8, 2016

The use of patients' own cancer cells for in vitro selection of the most promising treatment is an attractive concept in personalized medicine. Human carcinoma cells from malignant pleural effusions (MPEs) are suited for this purpose since they have already adapted to the liquid environment in the patient and do not depend on a stromal cell compartment. Aim of this study was to develop a systematic approach for the in-vitro culture of MPEs to analyze the effect of chemotherapeutic as well as targeted drugs.

Methods: MPEs from patients with solid tumors were selected for this study. After morphological and molecular characterization, they were cultured in medium supplemented with patient-derived sterile-filtered effusion supernatant. Growth characteristics were monitored in real-time using the xCELLigence system. MPEs were treated with a targeted therapeutic (erlotinib) according to the mutational status or chemotherapeutics based on the recommendation of the oncologists. Results: We have established a robust system for the ex-vivo culture of MPEs and the application of drug tests in-vitro. The use of an antibody based magnetic cell separation system for epithelial cells before culture allowed treatment of effusions with only moderate tumor cell proportion. Experiments using drugs and drug-combinations revealed dose-dependent and specific growth inhibitory effects of targeted drugs.

Conclusions: We developed a new approach for the ex-vivo culture of MPEs and the application of drug tests in-vitro using real-time measuring of cell growth, which precisely reproduced the effect of clinically established treatments by standard chemotherapy and targeted drugs. This sets the stage for future studies testing agents against specific targets from genomic profiling of metastatic tumor cells and multiple drug-combinations in a personalized manner.

Read more

Scientific paper
Application

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The RTCA DP Analyzer has three integrated stations for E-Plates 16 or CIM-Plates 16

show detail

Located inside a tissue culture incubator, it is capable of switching any one of the wells on the E-Plate 96 to the RTCA Analyzer for impedance measurement

show detail

Located inside a tissue culture incubator, it is capable of switching any one of the wells on any of six E-Plates to the RTCA Analyzer for impedance measurement

show detail

Instrument can be integrated with automated liquid handling platforms or a robotic plate handler from different vendors

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey